Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Int J Med Microbiol ; 314: 151612, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38394878

ABSTRACT

Across the globe, hand hygiene (HH) is promoted to fight the spread of healthcare associated infections. Despite multiple ongoing HH campaigns and projects, the healthcare associated infection rates remain high especially in low- and middle-income countries. In the narrative overview presented here, we aim to share objectives, framework, successes and challenges of our long-term partnership in Guinea to offer guidance for other projects aiming to sustainably improve HH.


Subject(s)
Cross Infection , Hand Hygiene , Humans , Guinea , Capacity Building , Cross Infection/prevention & control
2.
BMJ Case Rep ; 20162016 Oct 24.
Article in English | MEDLINE | ID: mdl-27797815

ABSTRACT

Piperacillin-tazobactam is an antipseudomonal antibiotic frequently used in patients with cystic fibrosis (CF) to treat pulmonary exacerbations. Drug-induced immune haemolytic anaemia is a rare complication during treatment with piperacillin. So far, piperacillin-induced immune haemolytic anaemia (PIHA) is regarded as an acute and severe haemolytic anaemia resulting into life-threatening events. Here we report on a patient with mild PIHA, which did not result in any clinical symptoms or necessity for treatment. To the best of our knowledge, this is the first case report of PIHA without an acute severe haemolytic anaemia. Further research is needed to clarify if this case is a solitary clinical manifestation of PIHA or if mild clinical courses of PIHA might be under-reported. Cases of PIHA have been largely reported in patients with CF. This unequal distribution maybe due to the frequent administration of piperacillin for pulmonary exacerbation in patients with CF or due to CF-related cofactors of yet unknown aetiology.


Subject(s)
Anemia, Hemolytic/chemically induced , Anti-Bacterial Agents/adverse effects , Cystic Fibrosis/complications , Penicillanic Acid/analogs & derivatives , Adult , Female , Humans , Penicillanic Acid/adverse effects , Piperacillin/adverse effects , Piperacillin, Tazobactam Drug Combination
3.
J Heart Valve Dis ; 17(4): 465-72, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18751477

ABSTRACT

BACKGROUND AND AIM OF THE STUDY: Growth factor-dependent cell proliferation can cause in-stent neointimal hyperplasia. The study aim was to evaluate whether oral everolimus inhibits the intimal proliferation associated with the implantation of prosthetic pulmonary valved stents. METHODS: Prosthetic pulmonary valves were implanted in 12 pigs (mean bodyweight 25 kg) using a transcatheter technique. Tricuspid valves were prepared from a titanium-coated polymer and sewn into a self-expanding nitinol stent (diameter 20 mm). Valved stents were implanted in the pulmonary position, where they remained for three months. In six animals, treatment with 2 mg/kg everolimus (Certican; Novartis) per day was started three days before implantation and continued throughout the course of the experiment. The other six pigs acted as controls. Adjuvant anticoagulation treatment consisted of acetylsalicylic acid and oral clopidogrel. After three months, hemodynamic valve function was investigated at catheterization and with MRI. At postmortem investigation the valved stents were explanted and subjected to macroscopic, histological and electron microscopic examination. RESULTS: There were no adverse side effects due to everolimus treatment. The overall mean everolimus plasma level during the study was 4.2 +/- 2.4 ng/ml. MRI revealed intact valve function with a regurgitation fraction of 7.3 +/- 4.2% in controls and 4.3 +/- 3.1% in the everolimus group (p <0.01). On macroscopic inspection and histological examination, the everolimus group showed only a thin tissue coverage of the stent struts. The valve cusps were free from intimal thickening, and electron microscopy showed a thin continuous cellular coating. In contrast, substantial neointimal formation was noted in controls. Tissue neogenesis was pronounced at the base of the valve, extended to the valve cusps, and caused valve thickening and foreshortening. CONCLUSION: The oral administration of everolimus effectively inhibits tissue neogenesis in pulmonary valved stents in pigs.


Subject(s)
Cell Proliferation/drug effects , Hyperplasia/prevention & control , Immunosuppressive Agents/therapeutic use , Sirolimus/analogs & derivatives , Stents/adverse effects , Animals , Everolimus , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation , Hemodynamics , Hyperplasia/etiology , Hyperplasia/pathology , Immunosuppressive Agents/pharmacology , Microscopy, Electron, Scanning , Pulmonary Valve , Sirolimus/pharmacology , Sirolimus/therapeutic use , Swine , Tunica Intima/cytology , Tunica Intima/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL